Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that combining Lexaria’s DehydraTECH(TM) delivery technology with generic nanotech techniques has been proven to deliver 1,137% more cannabidiol (“CBD”) into animal brain tissue following oral ingestion than certain existing industry formulations. According to the update, the results were confirmed in recent testing based on Lexaria’s series of animal studies it announced that it was beginning on March 20, 2019. Results from the studies with multiple objectives, including developing a better understanding of how effectively edible forms of cannabinoids cross the blood-brain-barrier to enter brain tissue, continue to generate additional data.
To view the full press release, visit http://cnw.fm/B9mMf
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its disruptive delivery technology, which promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000
For more information please visit https://www.CannabisNewsWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor
The post CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH(TM) Combined with Nanotech Delivers 1,137 Percent More CBD into Animal Brain Tissue appeared first on CannabisNewsWire.
READ MORE: https://www.cannabisnewswire.com/cannabisnewsbreaks/cannabisnewsbreaks-lexaria-bioscience-corp-s-cse-lxx-otcqx-lxrp-dehydratechtm-combined-with-nanotech-delivers-1137-percent-more-cbd-into-animal-brain-tissue/